Bernd Schulz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bernd Schulz has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Marrone
Department of Pharmacy, University “G. D'Annunzio” of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
1 shared publication - Angela Casini
Chair of Medicinal and Bioinorganic Chemistry, School of Natural Sciences, Department of Chemistry, Technical University of Munich, Lichtenbergstr. 4, D-85748 Garching b. München, Germany
1 shared publication - Claudia Schmidt
Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany
1 shared publication - Felix Alexander Böhm
Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany
1 shared publication - Guillermo Moreno-Alcántar
Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany
1 shared publication - Iogann Tolbatov
Department of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, Via Vienna 2, 07100 Sassari, Italy
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (10) , 4957-4966
Bioactivity studies of organometallic Cp*Rh( iii ) and Au( i ) NHC complexes bioconjugated to integrin binding peptides
Au( i ) and Rh( iii ) cRGD peptide-conjugates were developed for cancer targeting. Experiments and DFT models showed that metal integration uniquely impacts integrin binding and cellular uptake, guiding future targeted metallodrug design.
- 22 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (10) , 4957-4966
Open AccessBioactivity studies of organometallic Cp*Rh( iii ) and Au( i ) NHC complexes bioconjugated to integrin binding peptides
Au( i ) and Rh( iii ) cRGD peptide-conjugates were developed for cancer targeting. Experiments and DFT models showed that metal integration uniquely impacts integrin binding and cellular uptake, guiding future targeted metallodrug design.